Healthcare
Regenexbio
Recorded December 10, 2025
Regenxbio [NASDAQ: RGNX] has three assets in pivotal trials with the potential to become standard of care in markets worth a total of $26B.
Regenxbio [NASDAQ: RGNX] has three assets in pivotal trials with the potential to become standard of care in markets worth a total of $26B.
Developing highly targeted antibiotics that have the potential to reduce the core symptoms of Autism
Carbon GeoCapture is a global leader in the development of affordable, safe and effective carbon sequestration technology
NextTrip (NASDAQ: NTRP) is a travel discovery and booking platform built to disrupt an industry that’s been stagnant for 30 years
PACE has developed breakthrough Virtual Power Plant AI that can turn HVAC units into power sources
Duo Oncology is a next-generation biotech company creating a nanomedicine platform that replaces chemotherapy for hard-to-treat cancers
Xgene is using its proprietary conjugate platform technology to provide highly effective non-opioid relief for acute and chronic pain
XSponse is a comprehensive AI-powered security ecosystem that unifies detection, alerting, and mass notification into one integrated platform.
Scout Discoveries is a vertically integrated exploration company that is ready to meet the demand for domestically sourced critical minerals
Auctus Vertical Body Tethering has received a Breakthrough Device Designation and Humanitarian Device Exemption Pathway from the FDA
BrainScope has a pipeline that spans stroke, Alzheimer’s, concussion, and beyond, and is uniquely positioned in a $21B+ global market
Innova Vascular is producing FDA-cleared medical devices that remove dangerous blood clots more effectively and safely than existing options.